Espinosa-Valdespino L, Quintal-Ramirez MJ

Language: Spanish
References: 24
Page: 329-333
PDF size: 411.85 Kb.

ABSTRACT

Background: The coexistence of myeloproliferative neoplasms (MPNs), specifically essential thrombocythemia and lymphoproliferative neoplasms, are a very rare finding with a frequency ‹ 1%.
Case report: We present the case of a woman with diagnosis of mycosis fungoides early stage IB, of 5 months of evolution, she received systemic treatment based on methotrexate orally for 4 months; after this, she started with important thrombocythemia reaching up to 1 200 000/mm³ platelets and leukocytosis ranging from 10 000 - 13000/mL. A study protocol for chronic myeloproliferative disease was performed, reporting 90% cellular bone biopsy, erythroid myeloid ratio 5:1, 25 megakaryocytes per mm³, some with hyperlobed nuclei, and giant nuclei. Karyotype: 46XX. PCR without expression of BCR/ABL. JAK 2 positive. The diagnosis of essential thrombocythemia was concluded.
Conclusion: There are several hypotheses seeking to elucidate the etiopathogenesis of the coexistence of myeloproliferative and lymphoproliferative neoplasms, some claim that they are precursors of the same multipotential stem cell, while others support that they are the result of a coincidence. More molecular studies are required to elucidate this unknown.

REFERENCES

1. Hauck G, Jonigk D, Kreipe H, Hussein K. Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms. Acta Haematol. 2013;129 (3):187-96.

2. Mousinho F, Santos PSE, Azevedo AP, Pereira JM, Lemos R, Matos S, et al. Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature. Mol Clin Oncol. 2018;9(3):347-9.

3. Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86(12):1007-12.

4. Bouchla A, Thomopoulos T, Papageorgiou S, Tsirigotis P, Bazani E, Gkirkas K, et al. Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience. Adv Hematol. 2019;2019:1486476.

5. Malhotra J, Kremyanskaya M, Schorr E, Hoffman R, Mascarenhas J. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. Clin Lymphoma Myeloma Leuk. 2014;14(1):31-6.

6. Hernández-Boluda JC, Cervantes F, Alvarez A, López- Guillermo A, Montserrat E. Non-Hodgkin’s lymphoma following untreated essential thrombocythemia. Leuk Lymphoma. 2000;36(3-4):421-3.

7. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61(1):10-5.

8. Ruiz-Argüelles GJ, López-Martínez B, Lobato-Mendizábal E, Ruiz-Delgado GJ. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos. Int J Hematol. 2002;75 (5):499-502.

9. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, riskstratification and management. Am J Hematol. 2019;94 (1):133-43.

10. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.

11. Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291-6.

12. González-Ramírez RA, Ocampo-Candiani J, Méndez- Olvera N, Gómez-Flores M. Micosis fungoides: biología y terapéutica. Derma Cosmética y Quirúrgica. 2006;4(4): 278-287.

13. Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematol Oncol Clin North Am. 2017;31(2): 297-315.

14. Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep. 2017;12(3):234-43.

15. Vannucchi AM, Masala G, Antonioli E, Chiara-Susini M, Guglielmelli P, Pieri L, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosomenegative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2068-73.

16. Saeidi K. Myeloproliferative neoplasms: Current molecular biology and genetics. Crit Rev Oncol Hematol. 2016;98: 375-89.

17. Shammo JM, Stein BL. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions. Hematol Am Soc Hematol Educ Program. 2016;2016(1):552-560.

18. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-79.

19. Bastidas-Torres AN, Cats D, Mei H, Szuhai K, Willemze R, Vermeer MH, et al. Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes Cancer. 2018;57(12):653-64.

20. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18(7): 1288-95.

21. Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk Res. 2009;33(6):854-5.

22. Haider M, Gangat N, Lasho T, Abou-Hussein AK, Elala YC, Hanson C, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91(4):390-4.

23. Tefferi A, Pardanani A. Essential Thrombocythemia. N Engl J Med. 2019;381(22):2135-44.

24. Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematol Oncol Clin North Am. 2017;31(2): 297-315.